



Editorial

Prevotella copri and the microbial pathogenesis of rheumatoid arthritis



Prevotella copri y la patogenia microbiana de la artritis reumatoide

José Moreno

Hospital Juárez de México, Dirección de Investigación, Av. Instituto Politécnico Nacional No. 5160, Col. Magdalena de las Salinas, Del. Gustavo A. Madero, C.P. 07760 México, D.F., Mexico

To be able to decide what is relevant in science was never as difficult as today. The proliferation of journals and the Internet are a source of all kinds of new descriptions and interpretations, many of them right, but many others wrong or misleading. Such is the case for rheumatoid arthritis (RA) that, despite all the knowledge and new therapies, still remains an enormous challenge for its understanding. Although RA therapy has reached high levels of reasonability and many new drugs, especially biologicals, are now directed at mediators of inflammation and tissue damage known to participate in RA,¹ most of its pathogenesis remains poorly understood. The recent finding that a high percentage of RA patients and mice with inflammatory RA-like arthritis are carriers of particular strains of bacteria in their microbiota^{2–4} could be a major advance in our understanding of the disease. But, without a critical approach, it might lead to additional confusion instead of the much needed clarification.

Historical perspective

Although several hints of familial occurrence of RA had long indicated that the disease affected only genetically susceptible individuals, the major steps in our understanding of RA started with the discovery of rheumatoid factor in 1948.⁵ This was the first indicator of the autoimmune origin of RA that led to a great deal of research, but did little to our understanding of the pathogenesis of RA. The next major step was the finding of the predominance of T lymphocytes in the rheumatoid synovial membrane,⁶ later shown to be predominantly CD4+,⁷ leading to the hypothesis that RA was mediated by T cells. This was reinforced with the discovery of the association of the major histocompatibility complex (MHC) class II (MHCII) allele HLA-DR4⁸ that led to the definition of the MHCII shared epitope (SE).^{9,10} More recently, the advent of systems biology has led to the identification of many (>100) genetic

susceptibility loci for RA.¹¹ Nevertheless, the single most important one still lies in the MHCII gene HLA-DRB1,¹¹ where DRB1 alleles encoding the shared epitope with the amino acid sequence QKRAA in residues 70–74 of the HLA-DRβ chain, or related sequences are highly susceptible to developing RA with a particular pattern of autoantibodies.¹² Finally, toward the end of the 20th century, the discovery of antibodies directed at citrullinated proteins¹³ reinstated B cells and humoral immunity as part of the RA pathogenesis.

With regard to the microbial pathogenesis of RA, early in the 20th century, considering that RA was a form of tuberculosis (the major view at the time in France), Forestier introduced gold therapy.¹⁴ Subsequent studies focused in the search of a specific etiologic agent for RA, including *Mycoplasma*¹⁵ and several viruses.^{16–18} By the beginning of the 1980s, the hypothesis of a single infectious agent in the etiology of RA was essentially abandoned. However, there is an increased rate of clinical infections in patients with early but not with established RA.^{19,20} This is not new, however, as in 1924 Billington and Crabbe already had considered that RA was triggered by hidden infections and the therapeutic approach proposed by them included removal of the infective focus, which in their view was, in decreasing order: dental (periodontal), throat/nose, gallbladder, and genitourinary.²¹ It is amazing to see how, nine decades later, our view has not changed much!

Thus, RA can be non-specifically triggered or exacerbated by a number of infections^{19,20} or by external chemical or physical agents, including tobacco smoking and silica, among others.^{22,23} Although the mechanism of association is not entirely clear, one possible explanation is activation of the innate immune system leading to costimulation, followed by activation of autoreactive T cells.

The microbiome

More recently, as in other pathologic states, the role of normal or abnormal microbiome (but not specific pathogens) has attracted a great deal of (probably too much) attention. Undoubtedly, the great loads of bacteria in our bodies, mainly the gut, are

E-mail addresses: jmoreno49@gmail.com, jose.moreno@salud.gob.mx

of major importance in shaping our physiology,²⁴ but we are still far from understanding many aspects of host–commensal interactions in normal and pathological states. For instance, males and females have qualitative and quantitative differences in immune competence and susceptibility to autoimmune disease.²⁵ In mice, these appear to be explained by the effects of male androgens on the gut microbiota, which leads to a lower immunoreactivity and decreased susceptibility to autoimmune diabetes. RA is more frequent in females, which could be related to the microbiota.²⁶

Recent studies yielded evidence of two possible links between particular Gram-negative anaerobic bacilli and RA development in humans. The first one is periodontal disease caused by *Porphyromonas gingivalis*^{27,28} and the second is the prevalence, in the gut microbiota, of *Prevotella copri*.³

But wait! As interesting and potentially relevant as these findings appear, one must be careful. Let us not forget that through the years, the etiology of RA has been attributed to conditions ranging from infections such as tuberculosis,¹⁴ amebiasis,²¹ Epstein Barr virus,¹⁷ Proteus²⁹; endocrine imbalance,³⁰ to surgical procedures,³¹ to mention just a few. In some cases it led, mostly by serendipity, to useful therapies (i.e. gold), but in others to harmful failures (insulin causing hypoglycemia). Although some of these considerations have been completely wrong, others are of importance because they are clues to identifying some of the predisposing and triggering factors for RA. Indeed it was the notion that RA was caused by hypoadrenalism and not its inflammatory nature that led Hench to the use of cortisone for RA.³²

***Porphyromonas gingivalis* and periodontal disease**

The possible link of particular periodontal pathogens to connective tissue damage, including RA, in the modern era was first proposed by Engel et al. (1978) in studies of human fibroblasts exposed to *Actinomyces viscosus* extracts,³³ whereas the relation of rapidly progressing periodontitis to HLA-DR4 was described by Katz et al.³⁴ Over the following years, studies from different groups established a link between *Porphyromonas gingivalis* and RA, leading some to believe that this bacterium was critical for the development of RA, or even the etiological agent, based on: (1) the high prevalence of *P. gingivalis* positive periodontal disease (PD) among RA patients and viceversa^{2,35}; (2) the presence of high titers of anti-*P. gingivalis* antibodies in RA²⁸; (3) *P. gingivalis* expresses an endogenous peptidyl-arginyl deiminase (PAD) capable of citrullinating human protein substrates³⁶; (4) periodontal treatment leads to amelioration of RA activity.³⁷ However, not all RA patients have PD and/or *P. gingivalis*.^{2,35} Moreover, anti-*P. gingivalis* antibodies do not predict rheumatoid arthritis.³⁸ Finally, native bacterial PAD, which is truncated, lacks enzymatic activity,³⁹ as opposed to previous studies that used recombinant (non truncated) bacterial PAD.³⁶ Does it mean that *P. gingivalis* has no role in the pathogenesis of RA? Probably not, but it is not a specific pathogen, but an incidental infectious agent non-specifically triggering autoimmunity. Thus, *P. gingivalis* is not the etiologic agent of RA.

The gut microbiota

Recent studies have brought a new partner that might help the understanding of the relationship between microbes, RA and other autoimmune diseases. Dan Littman and coworkers studied the gut microbiota in patients with new onset RA (NORA), compared to established (chronic) RA, psoriatic arthritis (PsA) and healthy individuals.³ A high proportion of NORA patients had significantly increased ratio of *Prevotella* over *Bacteroides* organisms. The *Prevotella* species in NORA patients was *Prevotella copri* with statistical significances of *P. copri* prevalence in NORA vs. healthy

individuals, chronic RA or PsA $p=0.00002612$, 0.000001031 and 0.01698 , respectively, very significant indeed. However, not all NORA patients had increased *P. copri*, indicating that it is a very important, but not unique, contributing factor for the development of RA.

Studies in mice have shown that the presence of segmented filamentous bacteria (SFB) in the microbiota contributes significantly to the development of autoimmune disease in genetically susceptible hosts.⁴ It has been shown that the composition of the gut microbiota contributes to shape the immune system into a proinflammatory state through differentiation of CD4+ T lymphocytes to the Th17 subset.⁴⁰ Gut SFB, but not *Bacteroides* drive Th17 development and enhance arthritis in mice.⁴¹ Littman and coworkers colonized mice intestines with *P. copri* to find that it favors Th17 development and experimental dextran sulfate sodium-induced colitis.³ This suggests that the role of *P. copri* in human RA could be similar, as Th17 lymphocytes are the major inducers of tissue damage in RA.⁴² On the other hand, *Porphyromonas gingivalis* also drives Th17 cell differentiation.^{43,44} Thus, Th17 induction represents an important link among at least two of the bacteria associated to RA and suggests that additional microbes will be identified in the future as associated to RA.

One final observation of potential importance was that the increased prevalence of *P. copri* in NORA patients was inversely related to positivity for the shared epitope. The authors interpret this finding as an indication that the role of *P. copri* in RA could be more important in patients with a lower load of genetic susceptibility loci, where exogenous triggers of the disease are critical.³ Whatever the mechanism, it deserves further investigation as it is relevant for the understanding of RA and could have therapeutic implications.

In conclusion, RA is a complex genetically determined inflammatory condition of autoimmune origin, where external agents, mainly microbes, contribute in a variable manner to its onset and to its flares. Analysis of the available information must always be careful and one must not create artificial links to explain apparent contradictions. It usually leads to confusion, and waste of time and money that could be used for rational research. As Casaubon points in Umberto Eco's novel *Focault's Pendulum* "I believe that you can reach the point where there is no longer any difference between developing the habit of pretending to believe and developing the habit of believing." Let us keep science free of this.

References

1. Ramiro S, Machado P, Singh JA, Landewe RB, da Silva JA. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. *Arthritis Res Therapy.* 2010;12:220.
2. Miikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, et al. Periodontitis and *Porphyromonas gingivalis* in patients with rheumatoid arthritis. *Arthritis Rheum.* 2014;66:1090–100.
3. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *eLife.* 2013;2:e01202.
4. Chappert P. Role of SFB in autoimmune arthritis: an example of regulation of autoreactive T cell sensitivity in the gut. *Gut Microbes.* 2014;5:259–64.
5. Rose HM, Ragan C, et al. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. *Proc Soc Exp Biol Med.* 1948;68:1–6.
6. Bankhurst AD, Husby G, Williams RC Jr. Predominance of T cells in the lymphocytic infiltrates of synovial tissues in rheumatoid arthritis. *Arthritis Rheum.* 1976;19:555–62.
7. Meijer CJ, de Graaff-Reitsma CB, Lafeber GJ, Cats A. In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies. *J Rheumatol.* 1982;9:359–65.
8. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. *N Engl J Med.* 1978;298:869–71.
9. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987;30:1205–13.

10. Watanabe Y, Tokunaga K, Matsuki K, Takeuchi F, Matsuta K, Maeda H, et al. Putative amino acid sequence of HLA-DRB chain contributing to rheumatoid arthritis susceptibility. *J Exp Med*. 1989;169:2263–8.
11. Huang W, Wang P, Liu Z, Zhang L. Identifying disease associations via genome-wide association studies. *BMC Bioinform*. 2009;10 Suppl. 1:S68.
12. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. *Arthritis Rheum*. 2006;54:38–46.
13. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. *J Clin Invest*. 1998;101:273–81.
14. Forestier J. Copper and gold salts in rheumatoid arthritis. *Ann Rheum Dis*. 1949;8:132–4.
15. Williams MH, Brostoff J, Roitt IM. Possible role of *Mycoplasma fermentans* in pathogenesis of rheumatoid arthritis. *Lancet*. 1970;7667:277–80.
16. Middleton PJ, Highton TC. Failure to show mycoplasmas and cytopathogenic virus in rheumatoid arthritis. *Ann Rheum Dis*. 1975;34:369–72.
17. Niedobitek G, Lisner R, Swoboda B, Rooney N, Fassbender HG, Kirchner T, et al. Lack of evidence for an involvement of Epstein-Barr virus infection of synovial membranes in the pathogenesis of rheumatoid arthritis. *Arthritis Rheum*. 2000;43:151–4.
18. Zhang D, Nikkari S, Vainionpää R, Luukkainen R, Yli-Kerttula U, Toivanen P. Detection of rubella, mumps, and measles virus genomic RNA in cells from synovial fluid and peripheral blood in early rheumatoid arthritis. *J Rheumatol*. 1997;24:1260–5.
19. Laskin MD, Pope JE, Krizova A, Ouimet JM, Goodwin JL. Are infections increased in rheumatoid arthritis (RA) prior to diagnosis? Results of a case control study of RA compared to non-inflammatory musculoskeletal disorders. *Scand J Rheumatol*. 2005;34:74–5.
20. Arleevskaya MI, Gabdoulkhakova AG, Filina YV, Miftakhova RR, Bredberg A, Tsybulkin AP. A transient peak of infections during onset of rheumatoid arthritis: a 10-year prospective cohort study. *BMJ Open*. 2014;4:e005254.
21. Billington SG, Crabbe S. Etiology and treatment of rheumatoid arthritis and allied diseases. *Br Med J*. 1924;3312:1087–9.
22. Parks CG, Conrad K, Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. *Environ Health Perspect*. 1999;107 Suppl. 5:793–802.
23. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. *Ann Rheum Dis*. 2006;65:366–71.
24. Actis GC. The gut microbiome. *Inflammation Allergy Drug Targets*. 2014;13:217–23.
25. Schuurs AH, Verheul HA. Effects of gender and sex steroids on the immune response. *J Steroid Biochem*. 1990;35:157–72.
26. Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, et al. Gender bias in autoimmunity is influenced by microbiota. *Immunity*. 2013;39:400–12.
27. Liao F, Li Z, Wang Y, Shi B, Gong Z, Cheng X. *Porphyromonas gingivalis* may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. *Med Hypotheses*. 2009;72:732–5.
28. Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, Cannella AC, et al. Antibody responses to *Porphyromonas gingivalis* (*P. gingivalis*) in subjects with rheumatoid arthritis and periodontitis. *Int Immunopharmacol*. 2009;9:38–42.
29. Ebringer A, Rashid T. Rheumatoid arthritis is caused by Proteus: the molecular mimicry theory and Karl Popper. *Front Biosci (Elite Ed)*. 2009;1:577–86.
30. Liefmann R. Endocrine imbalance in rheumatoid arthritis and rheumatoid spondylitis; hyperglycemia unresponsiveness, insulin resistance, increased gluconeogenesis and mesenchymal tissue degeneration; preliminary report. *Acta Med Scand*. 1949;136:226–32.
31. Kalliomaki L. Role of various surgical operations in the history of patients with rheumatoid arthritis. *Ann Rheum Dis*. 1954;13:341–3.
32. Hench PS, Kendall EC, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. *Proc Staff Meet Mayo Clin*. 1949;24:181–97.
33. Engel D, Schroeder HE, Page RC. Morphological features and functional properties of human fibroblasts exposed to *Actinomyces viscosus* substances. *Infect Immun*. 1978;19:287–95.
34. Katz J, Goultchin J, Benoliel R, Brautbar C. Human leukocyte antigen (HLA) DR4. Positive association with rapidly progressing periodontitis. *J Periodontol*. 1987;58:607–10.
35. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. *Arthritis Rheum*. 2012;64:3083–94.
36. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, et al. Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. *Arthritis Rheum*. 2010;62:2662–72.
37. Okada M, Kobayashi T, Ito S, Yokoyama T, Abe A, Murasawa A, et al. Periodontal treatment decreases levels of antibodies to *Porphyromonas gingivalis* and citrulline in patients with rheumatoid arthritis and periodontitis. *J Periodontol*. 2013;84:e74–84.
38. de Smit M, van de Stadt LA, Janssen KM, Doornbos-van der Meer B, Vissink A, van Winkelhoff AJ, et al. Antibodies against *Porphyromonas gingivalis* in seropositive arthralgia patients do not predict development of rheumatoid arthritis. *Ann Rheum Dis*. 2014;73:1277–9.
39. König MF, Paracha AS, Moni M, Bingham CO, Andrade F. Defining the role of *Porphyromonas gingivalis* peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. *Ann Rheum Dis*. 2014. <http://dx.doi.org/10.1136/annrheumdis-2014-205385> [ePub May 26].
40. Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. *Cell Host Microbe*. 2008;16:337–49.
41. Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity*. 2010;32:815–27.
42. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. *J Immunol*. 1999;162:1246–51.
43. Cai Y, Kobayashi R, Hashizume-Takizawa T, Kurita-Ochiai T. *Porphyromonas gingivalis* infection enhances Th17 responses for development of atherosclerosis. *Arch Oral Biol*. 2014;59:1183–91.
44. Moutsopoulos NM, Kling HM, Angelov N, Jin W, Palmer RJ, Nares S, et al. *Porphyromonas gingivalis* promotes Th17 inducing pathways in chronic periodontitis. *J Autoimmun*. 2012;39:294–303.